Display options
Cite
Zhang L, Song R, Gu D, et al. The role of GLI1 for 5-Fu resistance in colorectal cancer. Cell Biosci. 2017;7:17doi: 10.1186/s13578-017-0145-7.
Zhang, L., Song, R., Gu, D., Zhang, X., Yu, B., Liu, B., & Xie, J. (2017). The role of GLI1 for 5-Fu resistance in colorectal cancer. Cell & bioscience, 717. https://doi.org/10.1186/s13578-017-0145-7
Zhang, Lining, et al. "The role of GLI1 for 5-Fu resistance in colorectal cancer." Cell & bioscience vol. 7 (2017): 17. doi: https://doi.org/10.1186/s13578-017-0145-7
Zhang L, Song R, Gu D, Zhang X, Yu B, Liu B, Xie J. The role of GLI1 for 5-Fu resistance in colorectal cancer. Cell Biosci. 2017 Apr 13;7:17. doi: 10.1186/s13578-017-0145-7. eCollection 2017. PMID: 28413604; PMCID: PMC5390459.
Copy Download .nbib Format: NLM
Share it on

Cell Biosci. 2017 Apr 13;7:17. doi: 10.1186/s13578-017-0145-7. eCollection 2017.

The role of GLI1 for 5-Fu resistance in colorectal cancer.

Cell & bioscience

Lining Zhang, Ruolan Song, Dongsheng Gu, Xiaoli Zhang, Beiqin Yu, Bingya Liu, Jingwu Xie

Affiliations

  1. Shanghai Key Laboratory of Gastric Neoplasms, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025 China.
  2. Departments of Pediatrics, Biochemistry and Molecular Biology, Pharmacology and Toxicology, The Wells Center for Pediatrics Research and IU Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN 46202 USA.

PMID: 28413604 PMCID: PMC5390459 DOI: 10.1186/s13578-017-0145-7

Abstract

Colorectal cancer is a leading cause of cancer-related mortality worldwide, with Fluorouracil (5-FU)-based chemotherapy as the major treatment for advanced disease. Many patients with advanced colorectal cancer eventually succumb to the disease despite some patients responded initially to chemotherapy. Thus, identifying molecular mechanisms responsible for chemotherapy resistance will help design novel strategies to treat colorectal cancer. In this study, we established an acquired 5-FU resistant cell line, LoVo-R, from LoVo cells. Through exome sequencing, we discovered that elevated GLI1 signaling axis is a major genetic alteration in the 5-FU resistant cells. Hh signaling, a pathway essential for embryonic development, is an important regulator for residual cancer cells. We demonstrated that knockdown of

Keywords: Colorectal cancer; EMT; Fluorouracil; GLI1; Hedgehog

References

  1. Int J Cancer. 2015 Mar 1;136(5):E359-86 - PubMed
  2. Cancer Cell. 2013 Jan 14;23 (1):23-34 - PubMed
  3. Nat Rev Gastroenterol Hepatol. 2011 Feb;8(2):90-100 - PubMed
  4. Proc Natl Acad Sci U S A. 2007 May 15;104(20):8455-60 - PubMed
  5. Cancer Lett. 2013 Jan 28;328(2):325-34 - PubMed
  6. Clin Cancer Res. 2015 Oct 15;21(20):4686-97 - PubMed
  7. Cancer Cell. 2012 Sep 11;22(3):373-88 - PubMed
  8. J Clin Invest. 2016 Dec 1;126(12 ):4460-4468 - PubMed
  9. JAMA Dermatol. 2016 Apr;152(4):452-6 - PubMed
  10. CA Cancer J Clin. 2017 Jan;67(1):7-30 - PubMed
  11. Curr Cancer Drug Targets. 2013 Nov;13(9):963-72 - PubMed
  12. Ann Surg. 2016 Mar;263(3):434-9 - PubMed
  13. Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13432-7 - PubMed
  14. Oncotarget. 2016 Jun 28;7(26):40594-40620 - PubMed
  15. Cancer Chemother Pharmacol. 2015 Sep;76(3):471-9 - PubMed
  16. Mol Cancer Ther. 2012 Jul;11(7):1587-97 - PubMed
  17. Front Biosci (Landmark Ed). 2011 Jan 01;16:1651-62 - PubMed
  18. Am J Prev Med. 2017 Feb;52(2):224-228 - PubMed
  19. Oncogene. 2009 Nov 19;28(46):4065-74 - PubMed
  20. Cancer Res. 2007 Mar 1;67(5):2187-96 - PubMed
  21. Oncotarget. 2016 Jun 7;7(23):34322-40 - PubMed
  22. Curr Opin Genet Dev. 2013 Aug;23(4):429-37 - PubMed
  23. J Clin Oncol. 2012 Sep 10;30(26):3223-8 - PubMed
  24. Cancer Lett. 2011 Jan 28;300(2):197-204 - PubMed
  25. Clin Cancer Res. 2012 Feb 1;18(3):869-81 - PubMed
  26. Nature. 2014 Jul 3;511(7507):90-3 - PubMed
  27. Oncotarget. 2016 Nov 29;7(48):78698-78712 - PubMed
  28. Clin Cancer Res. 2015 Mar 1;21(5):1002-9 - PubMed
  29. Cancers (Basel). 2015 Nov 27;7(4):2330-51 - PubMed
  30. Sci Signal. 2013 Apr 02;6(269):pl1 - PubMed
  31. Cancers (Basel). 2016 Feb 15;8(2):null - PubMed
  32. J Cancer Res Clin Oncol. 2017 Feb;143(2):243-254 - PubMed
  33. Oncotarget. 2015 Oct 20;6(32):32622-33 - PubMed
  34. Cell Stem Cell. 2011 May 6;8(5):511-24 - PubMed
  35. Anticancer Res. 2014 Apr;34(4):1531-5 - PubMed
  36. Oncogene. 2010 Jan 28;29(4):469-81 - PubMed
  37. J Biol Chem. 2007 May 11;282(19):14048-55 - PubMed
  38. Cancer Res. 2013 Jun 1;73(11):3381-92 - PubMed
  39. Oncogene. 2016 Jun 30;35(26):3399-409 - PubMed
  40. Cancer Discov. 2012 May;2(5):401-4 - PubMed
  41. Sci Rep. 2015 Oct 16;5:15239 - PubMed
  42. Mol Cancer Ther. 2015 Mar;14(3):633-41 - PubMed
  43. Clin Cancer Res. 2013 Jan 1;19(1):258-67 - PubMed
  44. Cell Death Dis. 2014 Apr 17;5:e1183 - PubMed
  45. Cell Death Dis. 2014 Jan 09;5:e983 - PubMed

Publication Types